Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 56.7% in March

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 24,700 shares, a drop of 56.7% from the February 28th total of 57,000 shares. Based on an average daily trading volume, of 198,900 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Astellas Pharma Price Performance

ALPMY stock opened at $9.90 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The business has a 50-day simple moving average of $9.72 and a two-hundred day simple moving average of $10.47. The company has a market capitalization of $17.92 billion, a P/E ratio of -45.00 and a beta of 0.29. Astellas Pharma has a 52-week low of $9.05 and a 52-week high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share (EPS) for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. Research analysts expect that Astellas Pharma will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.